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Abstract
Objective
Feline leukaemia virus (FeLV) infection is a major infectious disease of cats, but its prevalence has decreased as
a result of management of infected animals and vaccination. Efficacy of vaccines is tested in vaccination/challenge
experiments which are unfortunately poorly representative of the natural conditions of infection and may in some
instances lead to biased conclusions. To overcome this limitation of traditional efficacy studies, we tested the
efficacy of a non-adjuvanted recombinant canarypox-FeLV vaccine in a natural contact challenge model, and
compared it to an adjuvanted commercially available vaccine.
Methods
Vaccinated and unvaccinated control cats were mixed with persistently viraemic cats and kept in close contact
for more than 6 months. Cats were regularly tested for p27 antigenaemia and viraemia. Cats that were found
positive for either p27 antigenaemia or viraemia for the last three blood samples were considered persistently
viraemic.
Results
This contact challenge resulted in a high rate of persistent viraemia in control cats (78%). Vaccination efficiently
protected cats against persistent viraemia with preventable fractions of 79% for the canarypox vectored vaccine
and 68% for the adjuvanted commercial vaccine.
Conclusion
The natural contact challenge model proved to be a potent method to reproduce FeLV challenge, confirming
that under appropriate conditions FeLV is efficiently transmitted. Despite the severity of the challenge, both
vaccines provided a strong and sustained protection against persistent viraemia over a 6-month contact period.
This study confirmed the efficacy of a non-adjuvanted canarypox-vectored FeLV vaccine against a contact
challenge mimicking the natural conditions of infection.
Keywords: FeLV, vaccine; Canarypox virus; Efficacy; Contact
challenge
Introduction
Feline leukaemia virus (FeLV) is a major pathogen of cats causing a
wide range of clinical syndromes [1,2]. It has been described as the
"most destructive of feline infectious diseases" [3] and an important
cause of death. The prognosis for persistently viraemic cats is typically
poor with over 80% dying within 3-5 years after diagnosis [4-6].
The prevalence of FeLV depends on the geography and the cat
population, typically ranging from 2-3% to more than 10% p27
positive cats in high-risk environment [7-11]. Overall the prevalence
has been reduced in some countries as a result of both vaccination and
management of infected cats. Nevertheless, FeLV infection still
remains a risk in some cat populations, such as certain free-roaming
cats [9,12] or even client-owned cats in some geographical areas
[13-15] which display higher prevalence rates. It is well recognized that
FeLV p27 antigen negative status can occur following exposure to
FeLV, as indicated by the presence of FeLV provirus in tissues or blood
[16,17]. Since most studies are based on FeLV p27 antigen detection, it
is therefore likely that FeLV exposure and infection are underestimated
in such studies.
Although they do not necessarily prevent infection [18,19], FeLV
vaccines are potentially able to prevent persistent viraemia and thereby
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the diseases caused by FeLV as well as the shedding of the virus [20].
Most vaccines available on the market are classical inactivated or sub-
unit adjuvanted vaccines. With the aim to reduce the incidence of
injection site reactions, a non-adjuvanted canarypox virus vectored
vaccine has been developed where the recombinant canarypox virus
vector expresses envelope glycoproteins (p15E and gp70) and capsid
proteins of FeLV A, which have been shown to provide protection
against FeLV oro-nasal challenge [21-23]. Efficacy data have been
published for the different types of vaccines but few comparative
studies are available [20]. In addition, most of the published studies
rely on artificial challenge models, using the intra-peritoneal route or
high doses of challenge virus with simultaneous administration of
glucocorticoids [24]. Although less commonly performed, natural
challenge models of infection are generally regarded as the most
valuable method of assessing FeLV vaccine efficacy, mimicking natural
infection as much as possible.
This study was designed to assess the efficacy of a non-adjuvanted
canarypox virus vectored vaccine (EURIFEL® FeLV renamed
PUREVAX® FeLV, Merial) and a sub-unit vaccine, LEUCOGEN® in a
natural challenge model of FeLV infection [25]. LEUCOGEN® is a p45




Specific pathogen free (SPF) kittens were used for the study and
housed in a confined environment. All kittens were FeLV negative by
p27 antigen screening (IDEXX, Westbrook, USA) prior to inclusion in
the study. The kittens were divided into four groups:
• Group A comprised 18 kittens which served as the source of
natural challenge. They were challenged at 8-9 weeks of age with 1
× 106 focus forming units of Glasgow-1 strain of FeLV-A with 0.25
ml administered into each nostril and 0.5 ml orally to induce
persistent viraemia.
• Groups B and C comprised 24 kittens in each and received one of
the two vaccines being tested
• Group D comprised 23 kittens given placebo to serve as controls.
• Cats from groups B, C and D were also shown to be free of
antibodies against gp70 at the time of inclusion. Allocation to these
groups B, C and D was performed using a computerized
randomization program based on age, sex, parentage and weight in
descending order of priority.
Vaccination
Kittens in Groups B and C were vaccinated according to the
manufacturer's recommendations. Kittens in group B were vaccinated
at 8-9 weeks of age and four weeks later with EURIFEL® FeLV
(renamed PUREVAX® FeLV), a non-adjuvanted recombinant
canarypox virus expressing the env and gag/pro genes of FeLV A
(vCP97). Kittens in group C were vaccinated at 9-10 weeks of age and
again three weeks later at 12-13 weeks of age with LEUCOGEN®
purchased from a veterinary drug wholesaler. Group D kittens received
subcutaneous injections of sterile phosphate buffered saline at 8-9
weeks of age and at 12-13 weeks of age as a placebo.
The four groups were initially kept in separate rooms. Two weeks
after cats in groups B and C received their second vaccination; the
kittens from all four groups were mixed and housed in the same room.
They shared litter pans, food bowls and water dishes for the remainder
of the trial. Kittens in Group A were approximately four weeks older
than kittens from Groups B, C and D.
Post-challenge follow-up
Blood samples were collected by jugular venipuncture from all
kittens every two weeks for the first 14 weeks and then every three
weeks until the end of the trial, 27 weeks after mixing. The blood
samples were tested using both a standard commercial ELISA for FeLV
p27 antigen (Inochem, Carnforth, UK or IDEXX, Westbrook, USA)
and virus isolation on QN10S cells based on the method of Jarrett et al.
(1982) [27]. Persistent viraemia was defined as positive viraemia
and/or antigenemia for the final three blood samples of the study or,
for the cats which were euthanized before the end of the trial, for the
three samples prior to death. Vaccine efficacy was calculated as the
preventable fraction (Table 2).
Statistical Analysis
The proportion of persistently viraemic cats in each group was
compared by 2 test or Fisher’s exact test (comparison between
vaccinated groups). The Kaplan-Meier Product-Limit method was
used to plot the “survival” curves defining the time to viraemia or
antigenaemia, and to compare the median time to viraemia or
antigenaemia (Log-rank test). The analyses were two-tailed and
conducted with SAS 9.2 (SAS Institute Inc, Cary, NC) or Statgraphics
Plus 5.1 (StatPoints Technologies Inc., Warrenton, VA). The type I
error was set to α=5%.
Results
Eleven out of 18 kittens in Group A became antigenaemic/viraemic
within four weeks of challenge and 14 were antigenaemic/viraemic by
the time of mixing (six weeks after challenge). Three of the remaining
kittens became antigenaemic/viraemic before the end of the trial and
the final kitten remained negative throughout. Four of the viraemic
kittens from Group A were euthanized during the trial-two due to
severe anaemia at 28 and 32 weeks after challenge, one due to an
abdominal mass at 23 weeks after challenge, and one due to
paraparesis one week before the trial terminated.
Results of p27 ELISA and virus isolation were highly consistent
overall, although viral isolation was slightly more sensitive than p27
ELISA (Table 1). Eighteen of 23 (78%) kittens from Group D became
persistently viraemic - one died of unrelated causes during the trial but
was persistently viraemic.
Four of the remaining 5 cats in this group became antigen and/or
virus isolation positive during the last three weeks of the trial but did
not fulfil the criteria for persistent viraemia. Four kittens from Group B
became persistently viraemic (time to onset of viraemia was
respectively 6, 10, 12 and 18 weeks, Figure 1). Only one other kitten in
this group tested positive (on virus isolation), at the end of the trial. Six
kittens from Group C became persistently viraemic (time to onset of
viraemia was 6 weeks for one cat and 18 weeks for the remainder) and
one other kitten became antigenaemic/viraemic on the two final two
tests of the trial.
The proportions of persistently viraemic kittens for each group and
the preventable fractions achieved by the two vaccines are shown in
Table 2.
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Neg 24 24 23
p27 0 0 0
VI 0 0 0
4
Neg 24 24 20
p27 0 0 2
VI 0 0 3
6
Neg 23 23 19
p27 0 1 3
VI 1 1 4
8
Neg 23 23 18
p27 1 1 5
VI 1 1 5
10
Neg 22 23 17
p27 2 1 6
VI 1 1 6
12
Neg 21 23 12
p27 2 1 7
VI 3 1 11
14
Neg 21 23 9
p27 3 1 13
VI 3 1 13
18
Neg 20 18 5
p27 4 6 17
VI 4 6 18
21
Neg 20 18 5
p27 4 6 17
VI 4 6 18
25
Neg 20 17 1
p27 4 6 20
VI 4 7 21
27
Neg 19 17 1
p27 4 7 21
VI 5 7 22
neg: neither antigenaemic nor viraemic
p27: antigenaemic; VI: viraemic; #: number of cats
Table 1: Antigenaemia and viraemia status of the cats after mixing with
Group A on week 0.
There was a significant difference in the proportion of persistently
viraemic kittens between the different groups (χ2 test; p<0.0001) but no












FeLV 24 4 17% 79%
Leucogen 24 6 25% 68%
Controls 23 18 78% -
Table 2: Preventable fraction in vaccinated groups (PF=(Pv-Pc)/(1-Pc)
where Pv is the proportion of vaccinated cats which became
persistently viraemic and Pc the proportion of controls which became
viraemic).
The time to positive viraemia or antigenemia was significantly
reduced in vaccinated groups (Log-rank test; p<0.001), and the
difference between vaccinated groups was not statistically significant
(Log-rank test; p=0.58).
Figure 1: Evolution of the rate of negative cats per group (expressed
as survival probability on y-axis in %) after mixing with Group A on
week 0 (x-axis in weeks). A negative cat does not have detectable
p27 antigenaemia nor viraemia.
Discussion
In the absence of identified correlate of protection, vaccine efficacy
has traditionally been evaluated using experimental challenge with a
virulent FeLV strain. The best practice should be to use a challenge
model as close as possible to the natural conditions of infection. Using
other routes of infection than the oro-nasal route or the concurrent
administration of corticosteroids may introduce a bias in the
assessment of vaccine efficacy. Although an oro-nasal challenge with a
virulent FeLV strain is feasible as shown in our study, the intra-
peritoneal route or the simultaneous administration of glucocorticoids
has frequently been used to increase the efficiency of FeLV challenge
[20,24,28]. However, the route of infection may have an impact on the
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outcome of an infectious challenge and consequently on the efficacy of
a vaccine candidate. As an example, Dunham and coll. showed that a
vaccine against FIV was able to provide some protection against an
intra-peritoneal challenge but not against an intra-muscular one [29].
Similarly, corticosteroids-induced immunosuppression may introduce
a bias in the evaluation of vaccine efficacy. Indeed, glucocorticoids
suppress cellular (Th1) immunity and promote humoral (Th2)
immunity [30]. As a consequence, the impact of corticosteroids on
vaccine efficacy may be different depending on the mode of action of
the vaccine. Furthermore, administration of a single high dose of
challenge virus to ensure a high rate of infection in controls (as
required by FeLV vaccine monograph) is not representative of natural
conditions and may be an unnecessary difficulty in the development of
an efficacious vaccine. The natural transmission is usually the result of
prolonged or repeated contacts between cats. In an attempt to address
this concern, we used an experimental model which simulates natural
transmission of infection and may enable a more reliable
determination of the efficacy of protection that can be expected under
field conditions.
In the FeLV vaccine monograph of the European Pharmacopeia, the
efficacy test for FeLV vaccines is stringent and requires that 80% of the
control cats become persistently viraemic. This is one of the reasons
why natural transmission contact challenge studies are not routinely
used to demonstrate the efficacy of FeLV vaccines, despite the fact that
using natural routes of infection for such studies may produce results
that are more likely to reflect the true efficacy of vaccines. In our study,
the rate of persistent viraemia in controls cats (78%) approached what
is often obtained in classical oro-nasal or intra-peritoneal challenges
[20]. In addition, three of the four kittens in the control group that did
not become persistently viraemic showed evidence of infection by the
end of the trial and it is likely that most, if not all, of these would have
become persistently viraemic if the follow-up period had been
extended. This demonstrates that our challenge model was rigorous
compared with previous natural models, which displayed lower
infection rates [31-37]. The origin of the cats, housing conditions
and/or the FeLV challenge strain may explain some of these
differences. The strong virulence of Glasgow-1 strain was indeed
illustrated by the appearance of clinical signs strongly suggestive of
FeLV infection in kittens from group A (anaemia, abdominal mass,
paraparesis).
The overall rate of antigenaemic cats observed in our study is much
higher than what is usually reported in the field. In some high-risk
environments the proportion of antigenaemic cats can reach 10-20%
[38,39], far lower than in the current study. However, those
populations included cats of varying ages and it is well recognized that
susceptibility to FeLV infection is higher in young kittens than in adult
cats [32,40], and the cats in our study were actually all young. Our
study confirmed that transmission of FeLV is very efficient in young
cats living in close contact and in confinement in a restricted
environment.
Results of p27 antigenemia and virus isolation on blood samples
were comparable in this study. Virus isolation appeared to be slightly
more sensitive than antigenaemia, although the ease of detecting
antigenaemia generally makes this the method of choice to assess the
FeLV status of cats in many clinical studies. In the European
Pharmacopeia, persistent antigenaemia or viraemia is defined by three
consecutive positive results or five positive results at any time during
the follow-up period. However, the results at the end of the trial may
be more relevant indicators of FeLV status and potential persistent
viraemia. This is particularly true for a natural challenge model where
it generally takes longer for persistent viraemia to become established.
In our study, comparable to previous reports [35], the time between
mixing the groups and the first detection of viraemia varied from 4 to
27 weeks and it took more than 21 weeks to get close to 80% of the
control cats persistently infected. This is likely to be the result of the
overall infectious pressure increasing as new cats became persistently
viraemic.
In recombinant canarypox-FeLV and LEUCOGEN® vaccinated cats,
only 4 and 6 cats out of 24 in each group became persistently viraemic
respectively. In both groups, one additional cat was positive by the end
of the study. Overall, both vaccines significantly reduced the risk of
persistent viraemia with preventable fractions of 79% and 68%
respectively. While we cannot rule out the possibility that those figures
would have changed if the cats had been kept in contact for a longer
period [32], we believe that contact for more than 6 months can be
considered as a good challenge model, especially given the infection
rate seen in the control cats. A contact challenge over a 6 month period
is likely to be a mix of immediate, late and repeated infections via the
natural route of transmission. This suggests that the canarypox-
vectored FeLV vaccine-induced immunity against FeLV was early and
sustained over the 6-month follow-up period. These results are
consistent with previous data demonstrating the efficacy of the non-
adjuvanted canarypox-vectored FeLV vaccine against classical
challenges performed 2-3 weeks or one year after vaccination
[19,21,22]. Of note, the canarypox-FeLV vaccine protected more than
80% of the cats against persistent viraemia as requested by the FeLV
monograph of the European Pharmacopeia.
In this study, infectious pressure increased with time while new cats
became persistently viraemic and thereby additional shedders of FeLV.
In that respect, the challenge model was likely more severe than in the
usual field conditions where prophylaxis against FeLV relies also on the
detection and isolation of FeLV positive cats to reduce the risk of
exposure for non-infected animals.
Conclusion
The natural challenge model to assess FeLV vaccines in this study
proved to be a potent method to reproduce FeLV challenge, confirming
that under appropriate conditions FeLV is efficiently transmitted.
Despite the severity of the challenge, both vaccines provided a
comparable and good protection against persistent viraemia over a 6-
month contact period which led to persistent viraemia in most of the
controls. This study confirmed the efficacy of a non-adjuvanted
canarypox-vectored FeLV vaccine against a contact challenge
mimicking the natural conditions of infection.
®All marks are the property of their respective owner.
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